Canada
· Delayed Price · Currency is CAD Bright Minds Biosciences Company Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety.
It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin.
Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Ian McDonald |
Contact Details
Address: 19 Vestry Street New York, British Columbia 10013 United States | |
| Website | brightmindsbio.com |
Stock Details
| Ticker Symbol | DRUG |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | October - September |
| Reporting Currency | CAD |
| ISIN Number | CA10919W4056 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ian McDonald | Co-Founder, Chief Executive Officer, President and Director |
| Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer and Director |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
| Alex Vasilkevich | Chief Operating Officer and Vice President of Corporate Development |